41X Stock Overview A biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Ardelyx, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Ardelyx Historical stock prices Current Share Price US$4.64 52 Week High US$9.12 52 Week Low US$4.15 Beta 0.83 1 Month Change 3.43% 3 Month Change -12.09% 1 Year Change -17.44% 3 Year Change 373.47% 5 Year Change -30.23% Change since IPO -68.97%
Recent News & Updates
Independent Chairman of the Board recently bought €942k worth of stock Nov 16
New minor risk - Shareholder dilution Nov 03
Third quarter 2024 earnings released: US$0.003 loss per share (vs US$0.03 profit in 3Q 2023) Nov 01
Ardelyx, Inc. to Report Q3, 2024 Results on Oct 31, 2024 Oct 17
Ardelyx, Inc. to Present Additional Data Supporting First-In-Class XPHOZAH (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology's Kidney Week Oct 16
Ardelyx, Inc. Announces Publication of A Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology Oct 09 See more updates
Independent Chairman of the Board recently bought €942k worth of stock Nov 16
New minor risk - Shareholder dilution Nov 03
Third quarter 2024 earnings released: US$0.003 loss per share (vs US$0.03 profit in 3Q 2023) Nov 01
Ardelyx, Inc. to Report Q3, 2024 Results on Oct 31, 2024 Oct 17
Ardelyx, Inc. to Present Additional Data Supporting First-In-Class XPHOZAH (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology's Kidney Week Oct 16
Ardelyx, Inc. Announces Publication of A Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology Oct 09
Robbins LLP Informs Ardelyx, Inc. Stockholders of the Class Action Aug 19
Ardelyx, Inc. Appoints Eric Foster as Chief Commercial Officer Aug 08
Second quarter 2024 earnings released: US$0.07 loss per share (vs US$0.08 loss in 2Q 2023) Aug 02
Forecast breakeven date moved forward to 2025 Aug 02
Ardelyx, Inc. Announces Publication of Two Plain Language Summaries from XPHOZAH®? (tenapanor) Clinical Trials in Current Medical Research and Opinion Jul 31
Ardelyx, Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 18
Forecast breakeven date pushed back to 2026 Jul 04 Ardelyx, Inc.(NasdaqGM:ARDX) dropped from Russell Small Cap Comp Value Index
Ardelyx, Inc. Chooses Not to File for TDAPA to Preserve Patient Access to XPHOZAH Jul 02
Chief Medical Officer recently sold €295k worth of stock Jun 10
Ardelyx, Inc. Announces Rodriguez Would Resign as Chief Commercial Officer May 25
President recently sold €226k worth of stock May 24
Insider recently sold €726k worth of stock May 12
Forecast breakeven date pushed back to 2026 May 03
First quarter 2024 earnings released: US$0.11 loss per share (vs US$0.13 loss in 1Q 2023) May 03
Ardelyx, Inc., Annual General Meeting, Jun 14, 2024 May 01
Ardelyx, Inc. to Report Q1, 2024 Results on May 02, 2024 Apr 20
Ardelyx, Inc. Announces the Appointment of Mike Kelliher as Executive Vice President, Corporate Development and Strategy Mar 26 Ardelyx, Inc. announced that it has received $50 million in funding Mar 06
Full year 2023 earnings released: US$0.30 loss per share (vs US$0.42 loss in FY 2022) Feb 23
Ardelyx, Inc. to Report Q4, 2023 Results on Feb 22, 2024 Feb 02
Ardelyx Announces Departure of Geoffrey Block as Board Member Nov 14
Ardelyx, Inc. Announces XPHOZAH(R) (tenapanor) Now Available in the United States Nov 08
Ardelyx Shares Positive Data from Studies of Xphozah®? (Tenapanor) At Asn Kidney Week 2023 Nov 04
Ardelyx, Inc. Provides Earnings Guidance for the Full Year 2023 Nov 01
Third quarter 2023 earnings released: EPS: US$0.03 (vs US$0.14 loss in 3Q 2022) Oct 31
Ardelyx, Inc. to Report Q3, 2023 Results on Oct 31, 2023 Oct 30
Insufficient new directors Oct 27
Ardelyx, Inc. Shares Positive Data on Symptom Response During Treatment with IBSRELA®? (tenapanor) for IBS-C and Hosts IBS-C Product Theater at ACG 2023 Oct 24
Ardelyx, Inc. Announces FDA Approval of XPHOZAH (tenapanor), a First-In-Class Phosphate Absorption Inhibitor Oct 18
Ardelyx, Inc. Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility Sep 29
New major risk - Shareholder dilution Aug 04
Second quarter 2023 earnings released: US$0.08 loss per share (vs US$0.18 loss in 2Q 2022) Aug 03
Ardelyx, Inc. to Report Q2, 2023 Results on Aug 02, 2023 Jul 28
Forecast breakeven date pushed back to 2025 May 30
Ardelyx, Inc. Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH(R) May 18
First quarter 2023 earnings released: US$0.13 loss per share (vs US$0.21 loss in 1Q 2022) May 05
Full year 2022 earnings released: US$0.42 loss per share (vs US$1.52 loss in FY 2021) Mar 03
FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor) Dec 30
Forecast to breakeven in 2024 Dec 30
Ardelyx Provides Update on FDA Appeal for XPHOZAH (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis Dec 17
Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis Nov 17
High number of new directors Nov 16
Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.42 loss in 3Q 2021) Nov 05
Ardelyx Presents New Data Analyses At Kidney Week 2022, Further Supporting the Clinical Relevance of Xphozah(R) (Tenapanor) Nov 04
Ardelyx, Inc Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in Japan Nov 01
Ardelyx, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 28
Ardelyx, Inc. to Present Poster Presentations on IBSRELA (Tenapanor) for Adult Patients with IBS-C At the American College of Gastroenterology 2022 Annual Scientific Meeting Oct 25
Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.45 loss in 2Q 2021) Aug 06
President recently sold €63k worth of stock Jun 10
Ardelyx Receives Letter from the Nasdaq Global Market May 29
First quarter 2022 earnings released: US$0.21 loss per share (vs US$0.34 loss in 1Q 2021) May 07
Ardelyx, Inc., Annual General Meeting, Jun 15, 2022 May 02
High number of new directors Apr 27
Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH(R) (tenapanor) Apr 26
Ardelyx, Inc. Completes Three Successful Phase 3 Pivotal Trials, and Two Additional Phase 4 Clinical Trials (OPTIMIZE and NORMALIZE) for XPHOZAH Apr 08
Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in Adults Apr 05
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 02
Ardelyx, Inc. to Report Q4, 2021 Results on Feb 28, 2022 Feb 24
Ardelyx, Inc. Receives an Appeal Denied Letter from the Office of Cardiology, Hematology, Endocrinology and Nephrology of the U.S. Food and Drug Administration Feb 11
Ardelyx Announces Launching of IBSRELA® Second Quarter of 2022 Dec 01
Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.20 loss in 3Q 2020) Nov 13
Ardelyx Announces Publication of 52-Week Phase 3 PHREEDOM Trial Sep 04
Second quarter 2021 earnings released: US$0.45 loss per share (vs US$0.28 loss in 2Q 2020) Aug 14
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Ardelyx Inc Aug 12
No longer forecast to breakeven Jul 21
Ardelyx, Inc. Provides Regulatory Update on New Drug Application for Tenapanor for Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis Jul 20
First quarter 2021 earnings released: US$0.34 loss per share (vs US$0.25 loss in 1Q 2020) May 07
Ardelyx, Inc. Announces Board Changes Mar 17
Ardelyx, Inc. Announces Board Changes Mar 16
Independent Director has left the company Mar 16
Full year 2020 earnings released: US$1.05 loss per share (vs US$1.47 loss in FY 2019) Mar 09
Revenue beats expectations Mar 09
New 90-day high: €5.77 Jan 14
New 90-day high: €5.75 Dec 17
Independent Chairman recently bought €826k worth of stock Dec 11
New 90-day high: €5.23 Dec 02
Ardelyx, Inc. Updates Its Progress with Respect to Its Small Molecule Potassium Secretagogue Program, RDX013 Nov 14
Third quarter 2020 earnings released: US$0.20 loss per share Nov 07
Revenue beats expectations Nov 07
New 90-day low: €4.25 Oct 22
New 90-day low: €4.52 Sep 27
President recently sold €503k worth of stock Sep 20
New 90-day low - €4.62 Aug 29
First half earnings released Aug 07
New 90-day low - €4.73 Aug 06
Ardelyx, Inc.(NasdaqGM:ARDX) dropped from Russell Microcap Value Index Jul 03 Shareholder Returns 41X DE Biotechs DE Market 7D -6.4% -2.9% -2.6% 1Y -17.4% -14.7% 6.9%
See full shareholder returns
Return vs Market: 41X underperformed the German Market which returned 7.1% over the past year.
Price Volatility Is 41X's price volatile compared to industry and market? 41X volatility 41X Average Weekly Movement 11.9% Biotechs Industry Average Movement 6.8% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 41X's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 41X's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder.
Show more Ardelyx, Inc. Fundamentals Summary How do Ardelyx's earnings and revenue compare to its market cap? 41X fundamental statistics Market cap €1.06b Earnings (TTM ) -€69.56m Revenue (TTM ) €241.37m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 41X income statement (TTM ) Revenue US$251.85m Cost of Revenue US$85.54m Gross Profit US$166.31m Other Expenses US$238.89m Earnings -US$72.58m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.31 Gross Margin 66.03% Net Profit Margin -28.82% Debt/Equity Ratio 79.0%
How did 41X perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/20 09:39 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Ardelyx, Inc. is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Timothy Chiang BTIG Mara Goldstein Cantor Fitzgerald & Co. Louise Chen Cantor Fitzgerald & Co.
Show 14 more analysts 
